The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant

References

• Ratanatharathorn V, Nash RA, Przepiorka D, et al Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303–2314.
   PubMed Web of Science ®Google Scholar
• Remberger M, Kumlien G, Aschan J, et al Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:674–682.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Anderlini P, Saliba R, et al Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695–1700.
   PubMed Web of Science ®Google Scholar
• Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978;148:1687–1698.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Carson E, Reynolds C, et al Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275–279.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Reynolds C, et al Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505–511.
   PubMed Web of Science ®Google Scholar
• Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004;104:2603–2606.
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT, et al Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756–762.
   PubMed Web of Science ®Google Scholar
• Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909–911.
   PubMed Web of Science ®Google Scholar
• Teshima T, Nagafuji K, Henzan H, et al Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009;90:253–260.
   PubMed Web of Science ®Google Scholar
• von Bonin M, Oelschlagel U, Radke J, et al Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875–879.
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F, et al Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273–277.
   PubMed Web of Science ®Google Scholar
• Prasad VK, Kernan NA, Heller G, O'Reilly RJ, Yang SY. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999;93:399–409.
   PubMed Web of Science ®Google Scholar
• van Heeckeren WJ, Fanning LR, Meyerson HJ, et al Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. Br J Haematol 2007;139:464–474.
   PubMed Web of Science ®Google Scholar
• Ferrara GB, Bacigalupo A, Lamparelli T, et al Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001;98:3150–3155.
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Baxter-Lowe LA, Confer D, et al Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–1930.
   PubMed Web of Science ®Google Scholar
• den Haan JM, Sherman NE, Blokland E, et al Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476–1480.
   PubMed Web of Science ®Google Scholar
• Gale RP, Bortin MM, van Bekkum DW, et al Risk factors for acute graft-versus-host disease. Br J Haematol 1987;67:397–406.
   PubMed Web of Science ®Google Scholar
• Hahn T, McCarthy PL Jr, Zhang MJ, et al Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008;26:5728–5734.
   PubMed Web of Science ®Google Scholar
• Goulmy E, Schipper R, Pool J, et al Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281–285.
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006;43:3–10.
   PubMed Web of Science ®Google Scholar
• Couriel DR, Saliba RM, Giralt S, et al Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004;10:178–185.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, et al Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756–762.
   PubMed Web of Science ®Google Scholar
• Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant 2008;14:365–378.
   PubMed Web of Science ®Google Scholar
• Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol 2008;21:101–117.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Beatty PG, Storb R, et al Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79–91.
   PubMed Web of Science ®Google Scholar
• Corvo R, Paoli G, Barra S, et al Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. Int J Radiat Oncol Biol Phys 1999;43:497–503.
   PubMed Web of Science ®Google Scholar
• Quaranta S, Shulman H, Ahmed A, et al Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 1999;91:106–116.
   PubMed Web of Science ®Google Scholar
• Patriarca F, Skert C, Sperotto A, et al The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006;34:389–396.
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005;27:247–249.
   PubMedGoogle Scholar
• Shimada M, Onizuka M, Machida S, et al Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br J Haematol 2007;139:458–463.
   PubMed Web of Science ®Google Scholar
• Sakoda Y, Hashimoto D, Asakura S, et al Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2007;109:1756–1764.
   PubMed Web of Science ®Google Scholar
• Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985;161:718–730.
   PubMed Web of Science ®Google Scholar
• Hess A, Thoburn C, Bright E, Horwitz L. Specificity of effector mechanisms in syngeneic graft-vs-host disease: recognition of the MHC class II invariant chain peptide (CLIP). Transplant Proc 1997;29:725–727.
   PubMed Web of Science ®Google Scholar
• Fukushi N, Arase H, Wang B, et al Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci USA 1990;87:6301–6305.
   PubMed Web of Science ®Google Scholar
• Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol 1994;152:1609–1617.
   PubMed Web of Science ®Google Scholar
• Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 2003;102:429–435.
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Evans JG, Singh A, et al Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277–285.
   PubMed Web of Science ®Google Scholar
• Miyara M, Amoura Z, Parizot C, et al Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175:8392–8400.
   PubMed Web of Science ®Google Scholar
• Clark FJ, Gregg R, Piper K, et al Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004;103:2410–2416.
   PubMed Web of Science ®Google Scholar
• Rieger K, Loddenkemper C, Maul J, et al Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006;107:1717–1723.
   PubMed Web of Science ®Google Scholar
• Zorn E, Kim HT, Lee SJ, et al Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903–2911.
   PubMed Web of Science ®Google Scholar
• Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007;110:3804–3813.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389–399.
   PubMed Web of Science ®Google Scholar
• Mutis T, van Rijn RS, Simonetti ER, et al Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2‐/‐gammac‐/‐ immunodeficient mice. Clin Cancer Res 2006;12:5520–5525.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang C, Yi T, et al In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008;112:2129–2138.
   PubMed Web of Science ®Google Scholar
• Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004;104:3804–3812.
   PubMed Web of Science ®Google Scholar
• Giorgini A, Noble A. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts. J Leukoc Biol 2007;82:1053–1061.
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Miller KH, et al Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973–2978.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol 2004;173:5467–5475.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, et al Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412–415.
   PubMed Web of Science ®Google Scholar
• Ordemann R, Hutchinson R, Friedman J, et al Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 2002;109:1249–1256.
   PubMed Web of Science ®Google Scholar
• Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 2001;13:1583–1593.
   PubMed Web of Science ®Google Scholar
• Lang TJ, Nguyen P, Peach R, Gause WC, Via CS. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function. J Immunol 2002;168:3786–3792.
   PubMed Web of Science ®Google Scholar
• Morris SC, Lees A, Finkelman FD. In vivo activation of naive T cells by antigen-presenting B cells. J Immunol 1994;152:3777–3785.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996;153:85–106.
   PubMed Web of Science ®Google Scholar
• Ron Y, De Baetselier P, Tzehoval E, Gordon J, Feldman M, Segal S. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells. Eur J Immunol 1983;13:167–171.
   PubMed Web of Science ®Google Scholar
• Ron Y, De Baetselier P, Gordon J, Feldman M, Segal S. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. Eur J Immunol 1981;11:964–968.
   PubMedGoogle Scholar
• Tzehoval E, De Baetselier P, Ron Y, Tartakovsky B, Feldman M, Segal S. Splenic B cells function as immunogenic antigen-presenting cells for the induction of effector T cells. Eur J Immunol 1983;13:89–94.
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Ron J, Katz ME. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987;138:1051–1055.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995;16:289–295.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu Y, Ramarathinam L, et al Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response. Int Immunol 1995;7:1353–1562.
   PubMed Web of Science ®Google Scholar
• Zhang C, Todorov I, Zhang Z, et al Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993–3001.
   PubMed Web of Science ®Google Scholar
• Iori AP, Torelli GF, De Propris MS, et al B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008;85:386–390.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003;22:S19–S27.
   PubMed Web of Science ®Google Scholar
• Zorn E, Miklos DB, Floyd BH, et al Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004;199:1133–1142.
   PubMed Web of Science ®Google Scholar
• Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007;220:251–269.
   PubMed Web of Science ®Google Scholar
• Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6. Immunology 2008;125:430–437.
   PubMed Web of Science ®Google Scholar
• Papadimitraki ED, Choulaki C, Koutala E, et al Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54:3601–3611.
   PubMed Web of Science ®Google Scholar
• She K, Gilman AL, Aslanian S, et al Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:386–397.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003;198:937–945.
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465–475.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107–6114.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009;113:3865–3874.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, et al Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785–798.
   PubMed Web of Science ®Google Scholar
• Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981;67:134–140.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424–1433.
   PubMed Web of Science ®Google Scholar
• Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954–966.
   PubMed Web of Science ®Google Scholar
• Uchida J, Lee Y, Hasegawa M, et al Mouse CD20 expression and function. Int Immunol 2004;16:119–129.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–174.
   PubMedGoogle Scholar
• Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005;44:15150–15158.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, et al CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383–3389.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823–3837.
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359–7368.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–445.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, et al Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457–2466.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Lu TY, Ng KP, Cambridge G, et al A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482–487.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D, et al B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580–2589.
   PubMed Web of Science ®Google Scholar
• Levesque MC. Translational Mini-Review Series on B Cell-Directed Therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009;157:198–208.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease–the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86–95.
   PubMedGoogle Scholar
• Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:–957.
   PubMed Web of Science ®Google Scholar
• Introna M, Golay J, Barbui T. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura? Haematologica 2003;88:482–484.
   PubMed Web of Science ®Google Scholar
• Filion MC, Proulx C, Bradley AJ, et al Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood 1996;88:2144–2150.
   PubMed Web of Science ®Google Scholar
• Stasi R, Cooper N, Del Poeta G, et al Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147–1150.
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R83.
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Gunnarsson I, Widhe M, et al Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62–74.
   PubMed Web of Science ®Google Scholar
• O'Neill SK, Cao Y, Hamel KM, Doodes PD, Hutas G, Finnegan A. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol 2007;179:5109–5116.
   PubMed Web of Science ®Google Scholar
• Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826–837.
   PubMed Web of Science ®Google Scholar
• Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063–2073.
   PubMed Web of Science ®Google Scholar
• Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001;60:523–526.
   PubMed Web of Science ®Google Scholar
• Folzenlogen D, Hofer MF, Leung DY, Freed JH, Newell MK. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol 1997;83:199–204.
   PubMedGoogle Scholar
• Tokunaga M, Fujii K, Saito K, et al Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176–182.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15:1005–1013.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Okano A, Akamatsu S, et al Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172–173.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WL, van't Veer MB, et al Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537–543.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Saliba RM, et al Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407–4412.
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P, Saliba RM, et al Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530–5536.
   PubMed Web of Science ®Google Scholar
• Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2006:390–397.
   PubMedGoogle Scholar
• Ratanatharathorn V, Logan B, Wang D, et al Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009;145816–824.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, et al Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62:43–52.
   PubMed Web of Science ®Google Scholar
• van Dorp S, Pietersma F, Wolfl M, et al Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009;15:671–678.
   PubMed Web of Science ®Google Scholar
• Arai S, Sahaf B, Jones C, et al Prophylactic rituximab after reduced intensity conditioning transplantation results in low chronic GVHD. Blood 2008;112(Suppl. 1): (Abstract 466).
   Google Scholar
• Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008;36:755–768.
   PubMed Web of Science ®Google Scholar
• Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5:564–576.
   PubMed Web of Science ®Google Scholar
• Halpern WG, Lappin P, Zanardi T, et al Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006;91:586–599.
   PubMed Web of Science ®Google Scholar
• Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48:406–417.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Witzig TE, Inwards DJ, et al Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:1105–1110.
   PubMed Web of Science ®Google Scholar
• Cohen SB. Updates from B cell trials: efficacy. J Rheumatol Suppl 2006;77:12–17.
   PubMedGoogle Scholar
• Furie R, Stohl W, Ginzler EM, et al Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109.
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C, et al Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61–72.
   PubMed Web of Science ®Google Scholar
• Baroni SS, Santillo M, Bevilacqua F, et al Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667–2676.
   PubMed Web of Science ®Google Scholar
• Svegliati S, Olivieri A, Campelli N, et al Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007;110:237–241.
   PubMed Web of Science ®Google Scholar
• Chung L, Fiorentino DF, Benbarak MJ, et al Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009;60:584–591.
   PubMed Web of Science ®Google Scholar
• Magro L, Mohty M, Catteau B, et al Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009;114:719–722.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Locatelli F, Zecca M, et al Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009;114:709–718.
   PubMed Web of Science ®Google Scholar